Rivaroxaban with or without aspirin in stable cardiovascular disease
BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive...
Summary: | BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events. Copyright © 2017 Massachusetts Medical Society. |
---|---|
ISSN: | 00284793 |
DOI: | 10.1056/NEJMoa1709118 |
Similar Items
-
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
by: Connolly S.J.; Eikelboom J.W.; Bosch J.; Dagenais G.; Dyal L.; Lanas F.; Metsarinne K.; O'Donnell M.; Dans A.L.; Ha J.-W.; Parkhomenko A.N.; Avezum A.A.; Lonn E.; Lisheng L.; Torp-Pedersen C.; Widimsky P.; Maggioni A.P.; Felix C.; Keltai K.; Hori M.; Yusoff K.; Guzik T.J.; Bhatt D.L.; Branch K.R.H.; Cook Bruns N.; Berkowitz S.D.; Anand S.S.; Varigos J.D.; Fox K.A.A.; Yusuf S.; SALA J.; CARTASEGNA L.U.I.S.; VICO M.; HOMINAL M.A.; HASBANI E.; CACCAVO A.; ZAIDMAN C.; VOGEL D.; HRABAR A.; SCHYGIEL P.O.; CUNEO C.; LUQUEZ H.U.G.O.; MACKINNON I.J.; AHUAD GUERRERO R.A.; COSTABEL J.P.; BARTOLACCI I.P.; MONTANA O.; BARBIERI M.; GOMEZ VILAMAJO O.; GARCIA DURAN R.O.; SCHIAVI L.B.; GARRIDO M.; INGARAMO A.; BORDONAVA A.P.; PELAGAGGE M.J.; NOVARETTO L.; ALBISU DI GENNERO J.P.; IBANEZ SAGGIA L.M.; ALVAREZ M.; VITA N.A.; MACIN S.M.; DRAN R.D.; CARDONA M.; GUZMAN L.U.I.S.; SARJANOVICH R.J.; CUADRADO J.; NANI S.; LITVAK BRUNO M.R.; CHACON C.; MAFFEI L.E.; GRINFELD D.; VENSENTINI N.; MAJUL C.R.; LUCIARDI H.L.; GONZALEZ COLASO P.D.C.; FERRE PACORA F.A.; VAN DEN HEUVEL P.A.U.L.; VERHAMME P.; ECTOR B.A.V.O.; DEBONNAIRE P.; VAN DE BORNE P.; LEROY J.E.A.N.; SCHROE H.; VRANCKX P.; ELEGEERT I.V.A.N.; HOFFER E.; DUJARDIN K.A.R.L.; INDIO DO BRASIL C.; PRECOMA D.; ABRANTES J.A.; MANENTI E.; REIS G.; SARAIVA J.O.S.E.; MAIA L.; HERNANDES M.; ROSSI P.; ROSSI DOS SANTOS F.; ZIMMERMANN S.L.; RECH R.; ABIB E., et al.
Published: (2018) -
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
by: Bosch J.; Eikelboom J.W.; Connolly S.J.; Bruns N.C.; Lanius V.; Yuan F.; Misselwitz F.; Chen E.; Diaz R.; Alings M.; Lonn E.M.; Widimsky P.; Hori M.; Avezum A.; Piegas L.S.; Bhatt D.L.; Branch K.R.H.; Probstfield J.L.; Liang Y.; Liu L.; Zhu J.; Maggioni A.P.; Lopez-Jaramillo P.; O'Donnell M.; Fox K.A.A.; Kakkar A.; Parkhomenko A.N.; Ertl G.; Störk S.; Keltai K.; Keltai M.; Ryden L.; Dagenais G.R.; Pogosova N.; Dans A.L.; Lanas F.; Commerford P.J.; Torp-Pedersen C.; Guzik T.J.; Verhamme P.B.; Vinereanu D.; Kim J.-H.; Ha J.-W.; Tonkin A.M.; Varigos J.D.; Lewis B.S.; Felix C.; Yusoff K.; Steg P.G.; Aboyans V.; Metsarinne K.P.; Anand S.S.; Hart R.G.; Lamy A.; Moayyedi P.; Leong D.P.; Sharma M.; Yusuf S.
Published: (2017) -
Psychological Health of Surgeons in a Time of COVID-19: A Global Survey
by: Tan Y.Q.; Wang Z.; Yap Q.V.; Chan Y.H.; Ho R.C.; Hamid A.R.A.H.; Landaluce-Olavarria A.; Pellino G.; Gauhar V.; Chand M.; Wroclawski M.L.; Hameed B.M.Z.; Ling S.K.-K.; Sengupta S.; Gallo G.; Chiu P.K.-F.; Tanidir Y.; Tallada M.P.V.; Garcia B.N.; Colleoni R.; Abiddin Z.A.Z.; Campi R.; Esperto F.; Carrion D.; Elterman D.; Chung A.S.J.; Ng A.C.F.; Moschini M.; Rivas J.G.; Mayol J.; Teoh J.Y.-C.; Chiong E.; O'Kelly F.; Tarazi M.; Dziakova J.; Paesano N.; Frontali A.; Muhammad A.S.; Tebala G.D.; Baker A.; Lui R.N.; Sunkavalli C.; Cheng C.S.; Mazingi D.; Chen I.-H.A.; Vazquez-Martul D.; Khor V.; Orecchia L.; Gupta A.; Fidelis L.; Rashid A.; Mohammed O.T.; Iglesias C.; Tan Y.S.; Yang W.; Sanchez-Cordero S.; Abdussalam H.O.; Mehraj A.; Yildiz A.; Maheshwari P.N.; Choong A.M.T.L.; Patrick E.; Cortes-Guiral D.; Gomez M.J.
Published: (2023) -
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
by: Moayyedi P.; Eikelboom J.W.; Bosch J.; Connolly S.J.; Dyal L.; Shestakovska O.; Leong D.; Anand S.S.; Störk S.; Branch K.R.H.; Bhatt D.L.; Verhamme P.B.; O'Donnell M.; Maggioni A.P.; Lonn E.M.; Piegas L.S.; Ertl G.; Keltai M.; Bruns N.C.; Muehlhofer E.; Dagenais G.R.; Kim J.-H.; Hori M.; Steg P.G.; Hart R.G.; Diaz R.; Alings M.; Widimsky P.; Avezum A.; Probstfield J.; Zhu J.; Liang Y.; Lopez-Jaramillo P.; Kakkar A.K.; Parkhomenko A.N.; Ryden L.; Pogosova N.; Dans A.L.; Lanas F.; Commerford P.J.; Torp-Pedersen C.; Guzik T.J.; Vinereanu D.; Tonkin A.M.; Lewis B.S.; Felix C.; Yusoff K.; Metsarinne K.P.; Fox K.A.A.; Yusuf S.
Published: (2019) -
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
by: Eikelboom J.W.; Bosch J.; Connolly S.J.; Tyrwitt J.; Fox K.A.A.; Muehlhofer E.; Neumann C.; Tasto C.; Bangdiwala S.I.; Diaz R.; Alings M.; Dagenais G.R.; Leong D.P.; Lonn E.M.; Avezum A.; Piegas L.S.; Widimsky P.; Parkhomenko A.N.; Bhatt D.L.; Branch K.R.H.; Probstfield J.L.; Lopez-Jaramillo P.; Rydén L.; Pogosova N.; Keltai K.; Keltai M.; Ertl G.; Stoerk S.; Dans A.L.; Lanas F.; Liang Y.; Zhu J.; Torp-Pedersen C.; Maggioni A.P.; Commerford P.J.; Guzik T.J.; Vanassche T.; Verhamme P.; O'donnell M.; Tonkin A.M.; Varigos J.D.; Vinereanu D.; Felix C.; Kim J.-H.; Ibrahim K.S.; Lewis B.S.; Metsarinne K.P.; Aboyans V.; Steg P.G.; Hori M.; Kakkar A.; Anand S.S.; Lamy A.; Sharma M.; Yusuf S.
Published: (2022)